青霉素敏感和耐药肺炎球菌对新型氟喹诺酮类药物CFC - 222的敏感性

Susceptibility of penicillin-susceptible and -resistant pneumococci to CFC-222, a new fluoroquinolone.

作者信息

Kim J H, Kang J A, Lee Y, Lee K H, Lee J H, Choi E C, Kim B K

机构信息

Department of Microbial Chemistry, College of Pharmacy, Seoul National University, South Korea.

出版信息

J Antimicrob Chemother. 1998 Oct;42(4):527-30. doi: 10.1093/jac/42.4.527.

DOI:10.1093/jac/42.4.527

PMID:9818754

Abstract

The in-vitro activity of 12 antibacterial agents against 98 clinical isolates of Streptococcus pneumoniae, including 54 penicillin-resistant strains, was determined by a standardized broth microdilution method. CFC-222, vancomycin and imipenem were the most active agents, with an MIC90 of 0.5 mg/L for the test strains. CFC-222 was 16-fold more potent than ciprofloxacin and ofloxacin against all strains tested, including both penicillin-susceptible and -resistant strains. The anti-pneumococcal activity of fluoroquinolones was not affected by penicillin susceptibility. These results indicate that CFC-222 is potentially useful for treating infection caused by penicillin-resistant strains of S. pneumoniae.

摘要

采用标准化肉汤微量稀释法测定了12种抗菌剂对98株肺炎链球菌临床分离株（包括54株耐青霉素菌株）的体外活性。CFC - 222、万古霉素和亚胺培南是活性最强的药物，受试菌株的MIC90为0.5mg/L。CFC - 222对所有受试菌株（包括青霉素敏感和耐药菌株）的活性比环丙沙星和氧氟沙星强16倍。氟喹诺酮类药物的抗肺炎球菌活性不受青霉素敏感性的影响。这些结果表明，CFC - 222在治疗耐青霉素肺炎链球菌菌株引起的感染方面可能具有应用价值。